Skip to content

Study on the Effect of Ultra-early Autologous Cranioplasty on Neurological Function Recovery

Study on the Effect of Ultra-early Autologous Cranioplasty on Neurological Function Recovery: a Multicenter, Prospective, Open-label, Endpoint-blinded, Randomized Controlled Study

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07183540
Acronym
FAST-ECP
Enrollment
582
Registered
2025-09-19
Start date
2025-10-01
Completion date
2027-09-01
Last updated
2025-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cranial Defect

Keywords

Decompressive craniectomy and Cranioplasty, operation opportunity, ultra-early, Autologous skull

Brief summary

To compare the neurological recovery and complication rate of autogenous cranioplasty(CP) within 6 weeks after decompressive craniectomy (DC) with that of autogenous cranioplasty within 3\ 6 months after DC.

Detailed description

Objective: To compare the neurological recovery and complication rate of autogenous cranioplasty(CP) within 6 weeks after decompressive craniectomy (DC) with that of autogenous cranioplasty within 3\ 6 months after DC. Design: This study is a multi-center, prospective, randomized controlled, open-label trial. Interventions: Intervention measures were the time point of cranioplasty: within 6 weeks after decompressive craniectomy VS 3-6 months after decompressive craniectomy.

Interventions

PROCEDUREoperation opportunity-within 6 weeks after the DC operation.

The autologous skull repair surgery will be completed within 6 weeks after the DC operation.

PROCEDUREoperation opportunity-within 90 to 180 days after the DC operation.

The autologous skull repair surgery should be completed within 90 to 180 days after DC.

Sponsors

The Affiliated Hospital Of Guizhou Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

The study was open-label, endpoint-blinded, i.e. only the patients themselves and the treating physicians knew the randomization assignment results, baseline was evaluated by investigators who did not know the actual patient assignment, and primary endpoint visits were conducted by trained third parties who did not know what treatment the patients received.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Decompressive craniectomy due to craniocerebral trauma, cerebral ischemia and cerebral hemorrhage. 2. Age 18 - 80 years. 3. The first time for cranial repair. 4. unilateral skull defect. 5. Compliant with recommended decompressive bone flap surgery and autogenous decompressive bone flap after bone flap collection 6. signed the informed consent.

Exclusion criteria

1. Poor healing of skin flap (active infection, non-healing, necrosis, sinus, thin or poor blood supply, etc.). 2. Fracture of bone flap ≥2 pieces, partial open fracture 3. Intracranial infection before operation. 4. Severe bone metabolic diseases. 5. Long-term use of immunosuppressants. 6. Pregnant or lactating women. 7. Coagulation disorders. 8. Severe cardiopulmonary insufficiency. 9. It is estimated that the CP process cannot be completed within 6 weeks after the bone plate decompression surgery. 10. Skull defect size less than 25cm². 11. Life expectancy less than 1 year. 12. mRS greater than 1 before primary disease. 13. Diabetic patients. 14. Patients who are unable to cooperate with follow-up assessment (e.g. mental illness).

Design outcomes

Primary

MeasureTime frameDescription
modified Rankin Scale (mRS) 0-2at 180 (± 7) daysThe proportion of patients with a modified Rankin Scale (mRS) score of ≤ 2

Secondary

MeasureTime frameDescription
The incidence rate of intracranial hemorrhage90 days (±7 days) and 180 days (±7 days) after CP surgery
incidence of epilepsy90 days (±7 days) and 180 days (±7 days) after CP surgery
incidence of reoperation90 days (±7 days) and 180 days (±7 days) after CP surgery
mRS≤2 and mRS ≤390 (±7) days after CPProportion of mRS≤2 and proportion of mRS ≤3
mRS ≤3180 (±7) days after CPProportion of mRS≤2 and proportion of mRS ≤3
Glasgow Outcome Score (GOS)90 days (±7 days) and 180 days (±7 days) after CP surgeryMinimum score 1 and maximum score 8 with higher number being better outcome
hydrocephalus or Cerebrospinal fluid shunt surgery rate90 days (±7 days) and 180 days (±7 days) after CP surgeryThe incidence of hydrocephalus or CSF shunt surgery
Total medical expenses (excluding materials)At the time of discharge from CP, 90 (±7) days after CP-CP and 180 (±7) days after CP-CP at discharge
Complications related medical expensesAt the time of discharge from CP, 90 (±7) days after CP-CP and 180 (±7) days after CP-CP at discharge
Incidence of infection, poor healing, and subcutaneous effusion90 days (±7 days) and 180 days (±7 days) after CP surgery
Mini-Mental State Examination (MMSE) score90 days (±7 days) and 180 days (±7 days) after CP surgeryMinimum score 0 and maximum score 30 with higher score being better outcome

Other

MeasureTime frameDescription
Overall mortality rate180 (±7) days after CP surgeryAll etiology of mortality

Countries

China

Contacts

Primary ContactKaya Xu
xkaya@sina.com13984843194

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026